Be The Match BioTherapies and Cryoport announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations’ efforts to standardize critical elements of the cell therapy supply chain, as well as processes in apheresis and transplant center networks.
By pairing Cryoport’s expertise in temperature-controlled logistics with Be The Match BioTherapies’ expertise in apheresis center onboarding and management, case management and logistics, clinical research, and outcomes data collection and analysis, the two organizations will offer full end-to-end supply chain and outcomes support for companies developing and delivering autologous and allogeneic cell and gene therapies. An important part of the agreement is to integrate Be The Match BioTherapies’ MatchSource cell therapy supply chain software and Cryoport’s Cryoportal Logistics Management Platform. The outcome is a platform that manages more cell therapy products than any other solution in the marketplace, enabling cell and gene therapy companies to more rapidly discover, develop and deliver next-generation therapies.
Cryoport recently launched Chain of Compliance, a solution that offers full traceability and provides comprehensive data that, when combined with Be The Match BioTherapies’ assets, including MatchSource, manages risk and provides the industry with a cell therapy standardization platform. With services powered by the National Marrow Donor Program/Be The Match and more than 30 years of experience, Be The Match BioTherapies’ expertise includes the management of 22,000 cell and blood shipments annually and a successful compliance record in managing chain of identity.
“We are delighted to partner with Cryoport to support the growing cell and gene therapy industry,” said Chris McClain, MBA, vice president, Sales and New Business Development, Be The Match BioTherapies. “This new partnership will leverage the strengths of Cryoport and Be The Match BioTherapies to provide a unique set of standardized end-to-end workflow and logistics management services—beginning with cell harvest at apheresis centers, continuing through the supply chain, and ending with outcomes tracking—for the cell and gene therapy industry.”
“Be The Match BioTherapies is leading the charge to develop a more efficient and standardized cell therapy supply chain. We are pleased to join them in these industry-leading efforts and look forward to working together to support cell and gene therapy companies to more efficiently bring new medicines to patients,” said Mark Sawicki, chief commercial officer of Cryoport.